{"prompt": "['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 47 of 61', 'Medtronic', 'Additional measures to summarize are:', 'Incidence of device-related, procedure-related and/or therapy-related adverse events', 'Reportable device-related, procedure-related and/or therapy-related adverse events will be', 'summarized for subjects who are implanted and randomized under each amplitude setting. Device-', 'deficiencies will be summarized in the similar fashion. In addition, serious adverse events will be', 'summarized.', '14. Ethics', '14.1.Statement(s) of Compliance', 'The study will be conducted in accordance with this protocol, the ethical principles that have their origin', 'in the Declaration of Helsinki have been implemented in this clinical study by means of the informed', 'consent process, EC/IRB approval, study training, and risk benefit assessment. In addition, all applicable', 'laws and regulatory requirements of the country/ies in which the study is conducted will be followed', 'and in accordance with GCP.', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 48 of 61', 'Medtronic', 'In the US, the study will be conducted in accordance with 21 CFR\u00a711 Electronic Records,', 'Electronic Signatures, 21CFR\u00a750 Protection of Human Subjects, 21CFR\u00a756 IRB, and', '21CFR\u00a7803 Medical Device Reporting. Financial disclosures will be collected; however, this', 'study is not considered a \"covered study\" under 21 CFR\u00a754 Financial Disclosure by Clinical', 'Investigators.', 'In Europe, the study will be conducted in accordance with regional or national regulations, as', 'appropriate.', 'In Canada, the study will be conducted in accordance with Canada Medical Devices Regulations,', '1998 (SOR/98-282), and the Guidance document for Mandatory Problem Reporting.', 'Any additional requirements imposed by the IRB/EC or governing regulatory authority shall be followed,', 'if appropriate.', 'Medtronic will distribute the approved version of the CIP and all other materials required to conduct the', 'study. Prior to site activation, Medtronic will provide study training relevant and pertinent to the', 'involvement of personnel conducting study activities and investigator responsibilities. Medtronic will', 'not activate any site until the required approval/favorable opinion from the Institutional Review Board', '(IRB)/Ethics Committee (EC) or notification/approva from a regulatory authority have been obtained, if', 'appropriate.', 'Site personnel must inform Medtronic of any change in status of the IRB/EC approval once the site has', 'started enrollment.', '14.2. Principal Investigator Oversight', 'The Principal Investigator will provide adequate oversight to ensure the study is conducted in', 'accordance with all protocol requirements, all applicable regulatory requirements and any applicable', 'institutional requirements related to the conduct of clinical research. The Principal Investigator will', 'ensure no study-related activities occur prior to regulatory and IRB/EC approval. Any actions taken by', 'the IRB/EC with respect to the investigation will be forwarded to Medtronic as soon as possible. The', 'Principal Investigator is responsible for submitting all required reports to the sponsor and/or IRB/EC.', 'Regulatory reporting of AEs/DDs will be completed according to local regulatory requirements. It is the', 'responsibility of the Investigator to abide by any additional AE/DD reporting requirements stipulated by', 'the IRB/EC responsible for oversight of the study. Investigators should report serious adverse events,', 'device-, procedure- and therapy-related adverse events and device deficiencies to Medtronic after the', 'Investigator learns of the event in accordance with Table 14-1.', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 49 of 61', 'Medtronic', 'In addition, Principal Investigator, or designated personnel will provide Medtronic with the following', 'minimum information related to serious adverse events, device-, procedure-and/ortherapy-related', 'adverse events and device deficiencies:', 'Date of adverse event or device deficiency', 'Treatment provided', 'Resolution date', 'Assessment of seriousness', 'Relationship to the device, therapy and/or procedure', 'Failure to perform the investigator obligations or to complete corrective and preventive actions', 'identified during monitoring or auditing activities may result in Principal Investigator or site personnel', 'disqualification, and/or lead to suspension or termination of the study at the site.', 'Table 14-1 includes minimum reporting requirements for investigators participating in studies in Europe,', 'the US and Canada. Medtronic study personnel will immediately report Adverse Events and Device', \"Deficiencies, related to a CE marked or FDA approved device used during the study, to Medtronic's\", 'Compliant Handling Unit who will ensure prompt review and appropriate reporting. The Therapeutic', 'Products Directorate is a division of Heath Canada, and is responsible for regulating therapeutic', 'products including Food, Drugs, Medical Devices, Natural Health Products, Cells, Tissues and Organs and', 'Cosmetics. Table 14-1 includes minimum reporting requirements in Canada.', 'Table 14-1 Reporting Requirements', 'Serious Adverse Events (SAEs)', 'Investigator submit to:', 'Medtronic', 'Europe: Immediately after the investigator first learns of the event or of', 'new information in relation with an already reported event', 'All other geographies: Report to the sponsor, without unjustified delay, all', 'serious adverse events', 'IRB/EC', 'All geographies: Reporting timeframe as per local EC/IRB per local', 'requirement', 'Sponsor submit to:', 'EC/IRB', 'All geographies: Reporting timeframe as per local EC/IRB per local', 'requirement', 'Regulatory Authorities', 'All geographies: Reporting timeframe as per local requirement', 'Serious Adverse Device Effects (SADEs), Unanticipated Serious Device Effects (USADEs) and', 'Unanticipated Adverse Device Effects (UADEs)', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']\n\n###\n\n", "completion": "END"}